Source disclosure: January 07, 2026
ROHTO PHARMACEUTICAL CO.,LTD. [4527.T]
TOKYO, Jan 07 (Pulse News Wire) – Rohto Pharmaceutical CO.,LTD. (4527.T) announced today that its subsidiary will acquire shares of Thailand-based wellness firm Thann Oryza Co., Ltd.
(THANN). The acquisition was approved by the board of directors on January 07, 2026, and the agreement was signed on the same day. The deal involves acquiring 790,600 shares, representing 51% percent of voting rights, with the transaction value undisclosed due to confidentiality agreements. Post-acquisition, Rohto will own 790,600 shares, equivalent to 51% percent of voting rights. The share transfer is scheduled for March 31, 2026.
Rohto aims to leverage THANN's holistic approach and premium brand presence to accelerate growth in the global wellness sector. THANN, founded in 2003, operates across 14 countries and is known for its natural skincare and lifestyle products. The acquisition aligns with Rohto’s strategic vision to expand globally in health-related fields. Details on the impact of goodwill arising from the acquisition will be disclosed once finalized. Management expects the effect on consolidated earnings to be minor.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing